Hirayama Fumihiro, Takagi Shiro, Yokoyama Yoshito, Yamamoto Katsuhiro, Iwao Eiji, Haga Keiichiro
Protein Research Laboratories, Mitsubishi Pharma Corporation, 2-25-1 Shodai-ohtani, Hirakata 573-1153, Japan.
J Gastroenterol. 2002;37(10):779-84. doi: 10.1007/s005350200130.
In this study, to clarify whether Helicobacter pylori eradication alters the course of the development of gastric mucosal changes in the stomach, we examined the long-term effects of H. pylori eradication on H. pylori-inoculated gerbils.
A total of 40 H. pylori-inoculated gerbils were randomized and subjected, at 22 months after inoculation, to eradication treatment with dual therapy of omeprazole plus clarithromycin, or with therapy with a novel quinolone compound, Y-34867, alone. The animals were killed at the start of administration (control group) or at 8 months after the completion of therapy (vehicle or eradication-treatment groups).
Severe histopathological changes in the gastric mucosa were observed in all H. pylori-inoculated gerbils at the start of administration. At 8 months after completion of therapy, the frequency of gastritis, erosion, intestinal metaplasia, and gastric carcinoid in the eradication therapy groups was markedly reduced compared with that in the control and vehicle groups. Values for anti- H. pylori IgG titer, bacterial counts, and gastrin also decreased significantly.
These results suggest that H. pylori eradication may have had a therapeutic effect not only on gastritis, erosion, and gastric ulcer but also on glandular atrophy, intestinal metaplasia, and gastric carcinoid.
在本研究中,为了阐明根除幽门螺杆菌是否会改变胃黏膜变化的发展进程,我们研究了根除幽门螺杆菌对接种幽门螺杆菌的沙鼠的长期影响。
总共40只接种幽门螺杆菌的沙鼠被随机分组,并在接种后22个月接受奥美拉唑加克拉霉素的联合疗法或单独使用新型喹诺酮化合物Y-34867进行根除治疗。在给药开始时(对照组)或治疗完成后8个月(赋形剂组或根除治疗组)处死动物。
在给药开始时,所有接种幽门螺杆菌的沙鼠胃黏膜均观察到严重的组织病理学变化。治疗完成后8个月,根除治疗组胃炎、糜烂、肠化生和胃类癌的发生率与对照组和赋形剂组相比显著降低。抗幽门螺杆菌IgG滴度、细菌计数和胃泌素值也显著下降。
这些结果表明,根除幽门螺杆菌不仅可能对胃炎、糜烂和胃溃疡有治疗作用,而且对腺体萎缩、肠化生和胃类癌也有治疗作用。